Results 161 to 170 of about 365,101 (261)

Cytochrome c Oxidase Subunit COX4-1 Reprograms Erastin-Induced Cell Death from Ferroptosis to Apoptosis: A Transmitochondrial Study. [PDF]

Antioxidants (Basel)
Oliva CR, Flor S, Griguer CE.
europepmc   +1 more source

Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells

British Journal of Clinical Pharmacology, EarlyView.
Common genetic CYP2B6 variants correlate with adverse breast cancer outcome. The oestrogen metabolites estriol and 16‐epiestriol, which are formed downstream of CYP2B6‐catalysed 16α/β‐hydroxytestosterone, may be linked to elevated breast cancer risk and might increase due to the demonstrated CYP2B6 variants‐related metabolic shifts.
Marco Hoffmann, Julian Peter Müller, Stefan Düsterhöft, Sabrina Yamoune, Katja Susanne Just, Julia Carolin Stingl   +5 more
wiley   +1 more source

The role of vitamin C in melanoma cell death via activation of cytochrome C and TNF-α protein expression. [PDF]

Sci Rep
Sutedja EK, Arianto TR, Elgianda GS, Sutedja E, Lesmana R, Suwarsa O, Hindritiani R, Achdiat PA, Gunawan H, Setiabudiawan B.   +9 more
europepmc   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

Long-Distance Charge Transport between Cytochrome c and Complex III is Mediated by Protons and Reactive Oxygen Species. [PDF]

Small
Lagunas A, Gomila AMJ, Nin-Hill A, Guerra-Castellano A, Pérez-Mejías G, Samitier J, Rovira C, la Rosa MA, Díaz-Moreno I, Gorostiza P.   +9 more
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Correction: Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models. [PDF]

Cell Death Dis
Seervi M, Joseph J, Sobhan PK, Bhavya BC, Santhoshkumar TR.   +4 more
europepmc   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Putative long range mossy fiber sprouting and regional cytochrome c oxidase alteration in the hippocampus of patients with mesial temporal lobe epilepsy. [PDF]

Sci Rep
Tu T, Wan L, Zhang QL, Yang C, Zhou HS, Sun ZP, Long HY, Tang BS, Pan A, Tu E, Wang J, Yang ZQ, Li ZY, Yan XX.   +13 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

British Journal of Clinical Pharmacology, EarlyView.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto, Gabriël E. Jacobs, Joost C. van Mechelen, Laura G. J. M. Borghans, Johan G. C. van Hasselt, Linda B. S. Aulin   +5 more
wiley   +1 more source